Eyevensys
Pépinière - Paris Santé Cochin
29 rue du Faubourg Saint Jacques
Paris
75014
France
Tel: 33-0-1-84-79-10-60
Fax: 33-0-1-43-54-51-91
Website: http://www.eyevensys.com/
Email: contact@eyevensys.com
About Eyevensys
Eyevensys S.A.S is a privately held biotechnology company developing a game changing approach to express therapeutic proteins in situ for the treatment of major ophthalmic diseases.YEAR FOUNDED:
2008
LEADERSHIP:
Founder and CSO: Francine Behar-Cohen
CEO: Raffy Kazandjian
CLINICAL TRIAL:
Please click here for clinical trial information.
20 articles about Eyevensys
-
Eyevensys Announces Positive Preclinical Data Demonstrating Superiority of EYS809 over Aflibercept for Wet Age-Related Macular Degeneration (AMD) at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
4/24/2023
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, announces a scientific presentation at the 2023 Association for Research in Vision and Ophthalmology annual meeting in New Orleans, LA.
-
Eyevensys Recaps Highlights from Investigator Meeting and Presentations at the ARVO 2022 Annual Conference
5/11/2022
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today provided highlights from the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference held in Denver, Colorado.
-
Eyevensys to present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
4/29/2022
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases today announced that the company will be presenting preclinical data on its two lead candidates for geographic atrophy (GA) and wet AMD at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical
9/27/2021
Eyevensys today announces it has entered into strategic engagements with US-based medical device manufacturers Phillips-Medisize and Minnetronix Medical to develop the next generation of the company’s core technology.
-
Eyevensys Raises $12M in a Series B Plus Funding Round
8/4/2021
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, announces it has raised $12M in a Series B Plus funding round.
-
Eyevensys Named to French Tech 120 Program
2/15/2021
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announced it has been accepted into the French Tech 120 program for 2021.
-
Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosa
10/5/2020
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, announced the U.S. Food and Drug Administration has granted an orphan-drug designation for EYS611 for the treatment of retinitis pigmentosa.
-
BioSpace Movers & Shakers, March 13
3/13/2020
Companies strengthen their leadership teams and executive boards with this week's Movers & Shakers. -
Eyevensys Announces Executive Leadership Team Expansion
3/10/2020
Eyevensys announced the expansion of its leadership team with the appointment of Gerald Cagle as the Board’s Chairman, Francine Behar-Cohen to Chief Innovation Officer and Thierry Bordet as the Chief Scientific Officer.
-
Eyevensys Presents Initial Data from Phase I/II Trial of Innovative, Non-Viral Gene Therapy for Ocular Diseases at 11th Annual Ophthalmology Innovation Summit
10/11/2019
Eyevensys a private, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, this week presented results from part 1 of its phase I/II study for non-infectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco
-
Eyevensys Appoints New Board Member, Gerald Cagle
8/9/2018
– Eyevensys, a clinical stage biotech company developing non-viral gene therapies for ophthalmic diseases, today announced that Gerald (Jerry) Cagle, Ph.D., former Senior Vice President and Chief Scientific Officer at Alcon Laboratories has joined its Board of Directors.
-
Eyevensys Appoints Dr. Patricia Zilliox as CEO
12/12/2017
Dr. Zilliox, who joined the Eyevensys board in May 2016, has more than 25 years of global clinical development expertise.
-
Eyevensys Appoints Thierry Bordet Ph.D. As Pre-clinical Director
9/13/2017
-
Eyevensys Appoints Dr Ronald R. Buggage As Chief Medical Officer
9/5/2017
-
Eyevensys Announces The First-In-Human Treatment With Its GroundBreaking EyeCET ElectroTransfection Technology For Eye Diseases
5/9/2017
-
Eyevensys Receives Approval From The UK Medicines And Healthcare Products Regulatory Agency To Advance its EyeCET Platform Into Clinical Development
4/20/2017
-
Eyevensys Receives Approval From The French Product Security Regulatory Agency ANSM To Advance Its Eyecet Platform Into Clinical Development
4/11/2017
-
Eyevensys Appoints Leading Life Sciences Executive And Ophthalmology Expert Dr. Garth Cumberlidge As Chairman
3/21/2017
-
Eyevensys Announces Series A Extension Bringing Total Capital Raised To €9 Million
9/15/2016